Шрифт:
Закладка:
4089
National Center for Health Statistics. Health, United States, 2010: With Special Feature on Death and Dying. https://www.cdc.gov/nchs/data/hus/hus10.pdf. Published February 2011. Accessed May 5, 2022.; https://www.cdc.gov/nchs/data/hus/hus10.pdf
4090
Llarena N, Hine C. Reproductive longevity and aging: geroscience approaches to maintain long-term ovarian fitness. J Gerontol A Biol Sci Med Sci. 2021;76(9):1551–60. https://pubmed.ncbi.nlm.nih.gov/32808646/
4091
Gagnon A. Natural fertility and longevity. Fertil Steril. 2015;103(5):1109–16. https://pubmed.ncbi.nlm.nih.gov/25934597/
4092
Giri R, Vincent AJ. Prevalence and risk factors of premature ovarian insufficiency/early menopause. Semin Reprod Med. 2020;38(4–05):237–46. https://pubmed.ncbi.nlm.nih.gov/33434933/
4093
Stanford JL, Hartge P, Brinton LA, Hoover RN, Brookmeyer R. Factors influencing the age at natural menopause. J Chronic Dis. 1987;40(11):995–1002. https://pubmed.ncbi.nlm.nih.gov/3654908/
4094
Boutot ME, Purdue-Smithe A, Whitcomb BW, et al. Dietary protein intake and early menopause in the Nurses’ Health Study II. Am J Epidemiol. 2018;187(2):270–7. https://pubmed.ncbi.nlm.nih.gov/28992246/
4095
Conway F. Menopause matters: attending to the vitality of older women. J Women Aging. 2020;32(5):489–90. https://pubmed.ncbi.nlm.nih.gov/33225875/
4096
Minkin MJ. Menopause: hormones, lifestyle, and optimizing aging. Obstet Gynecol Clin North Am. 2019;46(3):501–14. https://pubmed.ncbi.nlm.nih.gov/31378291/
4097
Johnson A, Roberts L, Elkins G. Complementary and alternative medicine for menopause. J Evid Based Integr Med. 2019;24:2515690X19829380. https://pubmed.ncbi.nlm.nih.gov/30868921/
4098
Minkin MJ. Menopause: hormones, lifestyle, and optimizing aging. Obstet Gynecol Clin North Am. 2019;46(3):501–14. https://pubmed.ncbi.nlm.nih.gov/31378291/
4099
Pirhadi R, Sinai Talaulikar V, Onwude J, Manyonda I. It is all in the name: the importance of correct terminology in hormone replacement therapy. Post Reprod Health. 2020;26(3):142–6. https://pubmed.ncbi.nlm.nih.gov/32390508/
4100
Hunter MM, Huang AJ, Wallhagen MI. “I’m going to stay young”: belief in anti-aging efficacy of menopausal hormone therapy drives prolonged use despite medical risks. PLoS One. 2020;15(5):e0233703. https://pubmed.ncbi.nlm.nih.gov/32469976/
4101
Wilson RA, Wilson TA. The fate of the nontreated postmenopausal woman: a plea for the maintenance of adequate estrogen from puberty to the grave. J Am Geriatr Soc. 1963;11:347–62. https://pubmed.ncbi.nlm.nih.gov/14001078/
4102
Wilson RA, Wilson TA. The basic philosophy of estrogen maintenance. J Am Geriatr Soc.1972;20(11):521–3. https://pubmed.ncbi.nlm.nih.gov/5082121/
4103
Chew F, Wu X. Sources of information influencing the state-of-the-science gap in hormone replacement therapy usage. PLoS One. 2017;12(2):e0171189. https://pubmed.ncbi.nlm.nih.gov/28158240/
4104
Fugh-Berman A. The science of marketing: how pharmaceutical companies manipulated medical discourse on menopause. Women’s Reprod Health. 2015;2(1):18–23. https://www.tandfonline.com/doi/full/10.1080/23293691.2015.1039448
4105
Rubinstein H. Defining what is normal at menopause: how women’s and clinician’s different understandings may lead to a lack of provision for those in most need. Hum Fertil (Camb). 2014;17(3):218–22. https://pubmed.ncbi.nlm.nih.gov/24989874/
4106
Tatsioni A, Siontis GCM, Ioannidis JPA. Partisan perspectives in the medical literature: a study of high frequency editorialists favoring hormone replacement therapy. J Gen Intern Med. 2010;25(9):914–9. https://pubmed.ncbi.nlm.nih.gov/20425148/
4107
Rubinstein H. Defining what is normal at menopause: how women’s and clinician’s different understandings may lead to a lack of provision for those in most need. Hum Fertil (Camb). 2014;17(3):218–22. https://pubmed.ncbi.nlm.nih.gov/24989874/
4108
Minkin MJ. Menopause: hormones, lifestyle, and optimizing aging. Obstet Gynecol Clin North Am. 2019;46(3):501–14. https://pubmed.ncbi.nlm.nih.gov/31378291/
4109
Verkooijen HM, Bouchardy C, Vinh-Hung V, Rapiti E, Hartman M. The incidence of breast cancer and changes in the use of hormone replacement therapy: a review of the evidence. Maturitas. 2009;64(2):80–5. https://pubmed.ncbi.nlm.nih.gov/19709827/
4110
Auchincloss H, Haagensen CD. Cancer of the breast possibly induced by estrogenic substance. JAMA. 1940;114(16):1517–23. https://jamanetwork.com/journals/jama/article-abstract/1160126
4111
Anderson G, Cummings S, Freedman LS, et al. Design of the Women’s Health Initiative clinical trial and observational study. Control Clin Trials. 1998;19(1):61–109. https://pubmed.ncbi.nlm.nih.gov/9492970/
4112
Cummings SR. Evaluating the benefits and risks of postmenopausal hormone therapy. Am J Med. 1991;91(5B):14S-8S. https://pubmed.ncbi.nlm.nih.gov/1750410/
4113
Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. JAMA. 2002;288(3):321–33. https://pubmed.ncbi.nlm.nih.gov/12117397/
4114
Marsden J. Hormone replacement therapy and female malignancy: what has the Million Women Study added to our knowledge? J Fam Plann Reprod Health Care. 2007;33(4):237–43. https://pubmed.ncbi.nlm.nih.gov/17925102/
4115
Anderson GL, Limacher M, Assaf AR, et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women’s Health Initiative randomized controlled trial. JAMA. 2004;291(14):1701–12. https://pubmed.ncbi.nlm.nih.gov/15082697/
4116
Fugh-Berman A, Pearson C. The overselling of hormone replacement therapy. Pharmacotherapy. 2002;22(9):1205–8. https://pubmed.ncbi.nlm.nih.gov/12222561/
4117
Katz A. Observations and advertising: controversies in the prescribing of hormone replacement therapy. Health Care Women Int. 2003;24(10):927–39. https://pubmed.ncbi.nlm.nih.gov/14742130/
4118
Majumdar SR, Almasi EA, Stafford RS. Promotion and prescribing of hormone therapy after report of harm by the Women’s Health Initiative. JAMA. 2004;292(16):1983–8. https://pubmed.ncbi.nlm.nih.gov/15507584/
4119
Ravdin PM, Cronin KA, Howlader N, et al. The decrease in breast-cancer incidence in 2003 in the United States. N Engl J Med. 2007;356(16):1670–4. https://pubmed.ncbi.nlm.nih.gov/17442911/
4120
Fugh-Berman A. The science of marketing: how pharmaceutical companies manipulated medical discourse on menopause. Women’s Reprod Health. 2015;2(1):18–23. https://www.tandfonline.com/doi/full/10.1080/23293691.2015.1039448
4121
Roth JA, Etzioni R, Waters TM, et al. Economic return from the Women’s Health Initiative estrogen plus progestin clinical trial: a modeling study. Ann Intern Med. 2014;160(9):594–602. https://pubmed.ncbi.nlm.nih.gov/24798522/
4122
Majumdar SR, Almasi EA, Stafford RS. Promotion and prescribing of hormone therapy after report of harm by the Women’s Health Initiative. JAMA.
